FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
September 18, 2013
Results from the Heart and Stroke Foundation “Be Pulse Aware” ECG Screening Campaign will be released during Vascular 2013
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) confirms results from the use of the HeartCheck™ ECG Monitor will be presented at Vascular 2013, a one-time Canadian event of four separate scientific meetings: the Canadian Cardiovascular Congress, the Canadian Diabetes Association/Canadian Society of Endocrinology & Metabolism Professional Conference, the Canadian Stroke Congress and the Canadian Hypertension Congress. Vascular 2013 will be held in Montreal this October. Researchers from three University of Toronto teaching hospitals, the Centre for Innovation in Complex Care and the Heart and Stroke Foundation (“HSF”) of Canada participated in the national program that screened for Atrial Fibrillation (“AF”) as a risk factor for stroke.
The AF screening study was performed in association with the HSF 2013 “Be Pulse Aware” ECG Screening Campaign and was designed to test the feasibility and yield of mass Afib screening at public events using a diagnostic tool. The HeartCheck™ ECG Monitor was chosen as the tool to detect AF compared to a manual pulse check. The population demographics selected for the study targeted an at-risk population based on age. The primary endpoint of AF detection by pulse check, compared to ECG, was performed with adjudication by three independent cardiologists. The study is expected to also show the clinical relevance of single assessment population arrhythmia screening and the utility of ECG based screening versus pulse checks alone.
“The research team was interested in confirming whether incorporating a single-lead, handheld ECG device is a useful, reliable and easy to use method for community-based screening for AF. This is an important objective when we question, in daily clinical practice by family MDs, whether AF can be missed without doing an ECG. Positive results will support the use of the HeartCheck™ devices for credible use in the identification of arrhythmias such as AF, and will prove valuable in the increasing awareness of stroke prevention,” said Dr. Chi-Ming Chow, Director of Echocardiography and Vascular Lab, and Director of Medical Informatics, Department of Medicine, St. Michael’s Hospital, Associate Professor at University of Toronto.
“We look forward to the publication of the results from our first large scale arrhythmia screening use of the HeartCheckTM ECG Monitor and hope that it will establish our device as an effective tool for high-volume arrhythmia screening use in programs supporting community-based health initiatives, community outreach services and athlete screening, to name a few opportunities,” said Etienne Grima, Chief Executive Officer of CardioComm Solutions. “The study engaged nurses and nursing students to deploy the HeartCheck™ ECG Monitor. The devices are simple to use and the centralized review of recorded ECGs allows for efficient medical interpretation and confirmation of the presence, or absence, of arrhythmias and AF specifically. During 2013, we will continue to build relationships with physician and patient advocacy groups and to use results from our participation in national AF screening studies to increase credibility in the use of our devices and technologies. Our plan is to make HeartCheck™ a more recognizable name in the consumer and primary prevention markets and to invite other organizations interested in screening for cardiac arrhythmias as a risk factor for stroke or sudden cardiac death to contact us.”
More information regarding the HeartCheck™ products and SMART Monitoring solutions is available at the Company’s web site www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.